Gabapentin Dosing for Postherpetic Neuralgia
Start gabapentin at 100-300 mg at bedtime or 100-300 mg three times daily, then increase by 100-300 mg every 1-7 days as tolerated until reaching 1800-3600 mg/day in three divided doses. 1
Starting Dose
Begin with one of these regimens 2, 1:
- 100-300 mg at bedtime (single dose), OR
- 100-300 mg three times daily
The FDA-approved rapid titration schedule for postherpetic neuralgia specifically is 1:
- Day 1: 300 mg once daily
- Day 2: 600 mg/day (300 mg twice daily)
- Day 3: 900 mg/day (300 mg three times daily)
Titration Schedule
Increase by 100-300 mg every 1-7 days as tolerated until pain relief or dose-limiting side effects occur 2, 1. The titration phase typically takes 3-8 weeks 2.
Target Dose
The effective dose range is 1800-3600 mg/day in three divided doses 2, 1, 3. Key points:
- 1800 mg/day is the minimum effective dose demonstrated in clinical trials 1, 3
- Maximum dose is 3600 mg/day (1200 mg three times daily) 2, 1
- Doses above 1800 mg/day did not show additional benefit in clinical trials, though individual patients may respond 1
- The maximum interval between doses should not exceed 12 hours 1
Duration of Adequate Trial
Allow 3-8 weeks for titration plus at least 2 weeks at the maximum tolerated dose before determining treatment failure 2. An adequate trial can require 2 months or more 2.
Renal Dosing Adjustments
Reduce doses in renal impairment based on creatinine clearance 2, 1:
- CrCl ≥60 mL/min: 900-3600 mg/day (300-1200 mg TID)
- CrCl 30-59 mL/min: 400-1400 mg/day (200-700 mg BID)
- CrCl 15-29 mL/min: 200-700 mg/day (200-700 mg once daily)
- CrCl <15 mL/min: 100-300 mg/day (100-300 mg once daily)
- Hemodialysis: Maintenance dose based on CrCl plus supplemental 125-350 mg post-dialysis 1
Special Populations
Elderly patients: Use lower starting doses and slower titration due to age-related decline in renal function 2, 1.
Important Caveats
Gabapentin has nonlinear pharmacokinetics due to saturable absorption, which is why careful, gradual titration is essential 2. Starting too high or escalating too quickly increases side effects without improving efficacy.
Common dose-limiting side effects include dizziness (19-28% vs 7-8% placebo) and somnolence (14-21% vs 5-9% placebo), particularly during titration 2, 1, 3. These can be minimized by slow titration and bedtime dosing initially.
Do not abruptly discontinue gabapentin, as this may precipitate seizures in susceptible patients. Taper over at least 1 week 1.
The evidence shows that 32-38% of patients achieve substantial pain relief (≥50% reduction) with gabapentin 1800-3600 mg/day compared to 17-21% with placebo 4. The NNT is approximately 6 for substantial benefit 4.